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limits, a known low risk metastasis disease in papillary thyroid cancer, a chest X-ray
unmodiﬁed and the description in the scientiﬁc literature of iodine-131 uptake in
focal bronchiectasis mimicking metastatic thyroid cancer induced to monitor clinical
status without further investigations. Her serum TG remained undetectable at six-
month follow-up and I-131 whole-body at one-year follow-up showed the same lung
focal hot spots. A chest computed tomography scan was performed conﬁrming the
presence of bronchiectasis involving both lung ﬁelds without evidence of pulmonary
metastasis. Aberrant uptake of radioactive iodine is present not only in known in-
ﬂammatory disease of the lung, aspergilloma and respiratory bronchiolitis but false
positive iodine uptake can be present also in case of pulmonary involvement in CF.
P67 SPHENOID SINUS MUCOCELE IN A CYSTIC FIBROSIS CHILD
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A six years old male child affected with cystic ﬁbrosis presented to the ENT exam-
ination with a history of nasal obstruction and two episodes of intense headache.
A nasal ﬂexible endoscopy was performed showing a bulging of the all superior wall
of the nasal cavity, an anterior displacement of the medium turbinate’s root and a
reduction of the choana’s size, due to the mass occuping space. The CT scan showed
a homogeneous mass involving entirely the sphenoidal sinus, with an enlargement of
the whole cavity, the posterior portion of the ethmoidal sinuses, the superior and the
middle portion of the nasal cavities, and a partial portion of the choanal lumen. En-
hanced MRI was performed excluding a vascular pattern of the lesion. Thus, the ra-
diological features of these examinations suggested a big sphenoidal mucocele. The
patient was treated with antibiotical prophilaxis i.v. before the surgical treatment.
An endoscopic approach (FESS) in achieving marsupialization and drainage of the
sphenoidal mucocele was carried out. A sharp removal of anterior and inferior
bone walls was performed and a gentle suction of its content of suppurating thick
secretions was actuated.
The mucous within the mucocele cavity was sterile at Gram staining investigation.
The follow up included a clinical evaluation with rinoﬁibroscopy at 1–3–6 months
and an MRI at 6 months.
The marsupialization and drainage of the mucocele is believed to be the mainstay
of treatment and the endoscopic treatment seems to be the most successful tool in
carrying out this type of surgical management, according with the authors’ opinion
that a mini-invasive treatment is the best choice for mucoceles in children and young
adults, where an incision of an external approach can bring to cosmetic distortions.
Moreover this approach results in lower morbidity and complications than external
intranasal or intracranial tecniques; it has a very low rate of recurrence and allows
a good visualisation of the operative ﬁeld with minimal blood loss.
P68 CYSTIC FIBROSIS PATIENT WITH SEVERE RESPIRATORY
FAILURE: RAPID RESOLUTION OF ATELECTASIS WITH NIMV
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Cystic ﬁbrosis (CF) is a hereditary disease with a mild to severe pulmonary
involvement. The most frequent complications are pneumothorax, haemoptysis and
atelectasis. We report a case of one day resolution of atelectasis with the application
of noninvasive mechanical ventilation (NIMV) in a CF patient with bronchopneu-
mopathy, progressive chronic renal failure, malnutrition requiring nutritional support
and toxic multinodular goiter with tracheal compression previously treated with
radioiodine therapy.
A 44-year-old woman with a CF diagnosis at the age of 33, severe pulmonary
disease with an hypoxic hypercapnic respiratory insufﬁciency and chronic Pseu-
domonas aeruginosa infection was admitted to our CF Adult Unit for high-dose
antibiotic therapy because of a febrile pulmonary exacerbation conﬁrmed by an
important worsening of chest x-ray. After four weeks of therapy to overcome the
acute phase, the patient underwent renal biopsy to investigate the chronic renal
failure (amyloidosis associated with chronic disease), before evaluation for lung
transplant waiting list. The investigation was complicated by bladder tenesm and
macro-hematuria with required hemotransfusions and atropine-similar drugs. Due
to the difﬁculty to practice airways clearance techniques the respiratory involvement
worsened and, at the same time, at thorax examination a bronchial breath appeared
in left subclavicular and precordial region. Chest X-ray showed the presence of
“large left hemithorax opacity suggestive for atelectasis”. So we used NIMV for a
longer period of application (the patient was already irregularly performing because
of the discomfort) and with higher level of pressure support to 7 cmH20. The
increase of pressure and an intensive use of NIVM determined a rapid and important
reduction of atelectasis, as shown by the chest X-ray performed the following day,
and an improvement of respiratory exchanges and dyspnoea.
The case conﬁrmed that early, correct and intensive use of NIVM can lead to
atelectasis resolution without the use of invasive approaches.
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Pulmonary malformations are comprised in the spectrum of CCAM including
bronchial cysts and pulmonary sequestration. They all can complicate with repeated
infections, abscesses, or hemothorax, therefore elective removal is desirable as soon
as possible. In case of sequestration the resolution can be achieved also with simple
embolization of the feeding artery. Concern about diagnosis, timing and modality
of treatment can arise from associated pathology.
Case report: CC, female, born from healthy non-consanguineous parents, had a
prenatal diagnosis of CCAM in the left lung (magnetic resonance at 22 weeks).
Then surgery was scheduled soon after birth. She subsequently received a diagnosis
of CF for neonatal hypertrypsinogenaemia, followed by positive chloride sweat
test (103mEq/l) and extensive molecular analysis of the CFTR gene showing a
compound heterozygosity (R334W/2118del4). A CT scan was performed in the
neonatal period and it revealed a left pulmonary sequestration.
The CF diagnosis induced a more prudential approach and surgery was delayed in
favour of a more conservative treatment as a ﬁrst choice.
At 1 year of age, a CT angiography displayed intralobar pulmonary sequestration,
receiving blood supply from a large vessel originating from descending aorta.
The infant was in good nutritional status, with no respiratory symptoms but
occasional rhinitis. She is on regular chest physiotherapy with PEP-mask, presenting
no bacterial respiratory infection. At 16 months of age, coil embolization of the
abnormal feeding artery was successfully performed, obtaining a 80−90% loss of
vascolarization. At 30 months of age the infant is in good clinical conditions, with
normal growth and no respiratory symptoms.
The case is presented for the rarity of the association of the two pathologies (lung
malformation and CF) and because of the concern in the decision-making process
regarding treatment. Chest surgery in a CF infant should be avoided, if not strictly
needed; thus embolization was considered as the choice treatment in our case.
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CYSTIC FIBROSIS
L. Ratclif, A. Nigro, P. Vitullo. U.O.S. Cystic Fibrosis – Cerignola (FG), Italy
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing
problem in both the general population and cystic ﬁbrosis (CF) patients. MRSA is
recognized s a bacterial pathogen in CF patients, although its clinical effects can be
variable. The isolation of MRSA in the sputum of patients with CF had questionable
signiﬁcance; in many instances, it was considered to be related to colonization rather
than being directly related to deterioration in the course of pulmonary disease.
Aim: To determine determine whether MRSA infection has a deleterious effect on
the clinical status of patients with CF.
Methods: Patients with MRSA in respiratory cultures during a three year period,
September 2004-September 2007, were identiﬁed and compared with controls
matched for age, sex, and respiratory function. Respiratory function tests, anthro-
pometric data, symptoms and clinical signs, chest x-ray score were considered in
the evaluation of the two groups.
Results: From a clinic population of 86, 32 CF patients (22 boys, 10 girls, median
age 14 years) had positive sputum or cough swab cultures for MRSA. Thirty-three
age-sex-matched MRSA-negative controls were identiﬁed. Only 2 of 32 (6.3%)
MRSA-positive patients showed chronic colonization. In 30 of 32 (93.7%) patients
who were not receiving speciﬁc antibiotic therapy MRSA has been eradicated. Prior
to initial isolation 27/30 (90%) MRSA-positive CF patients received more antibiotic
treatments (oral quinolones in 70% of cases, oral cotrimoxazolo in 51%, intravenous
aminoglycosides in 37%, oral quinolones associated with nebulized tobramicin in
7%, oral/intravenous cephalosporins in 6% of children). Three of 30 (10%) MRSA-
positive patients were treated with no antibiotic therapies before MRSA acquisition.
There were no signiﬁcant differences between the two groups with respect to change
in weight, body mass index, decline in chest x-ray appearance, pulmonary function.
Conclusion: MRSA infection in children with CF does not signiﬁcantly affect
respiratory function; acquisition did not appear to directly affect the course of the
pulmonary disease in these patients, even though no patient received any treatment
for their MRSA. MRSA decolonization can be successful in a high proportion of CF
patients also without use of speciﬁc antibiotic protocols. Although more studies are
needed to evaluate the full signiﬁcance of MRSA colonization among patients with
CF, a judicious use of antibiotics and a segregation of in and out patients should
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be the key of any strategies designed to reduce the risk of MRSA acquisition by
patients with CF.
P71 CF NEWBORN SCREENING AND ITS PREVENTIVE EFFECT:
7 YEARS EXPERIENCE IN THE UMBRIA REGION
A. Angius, M. Stasi, T. Becchetti, M.C. Cardellini, L. Penta, M. Furbetta. Lab. di
Genetica Molecolare, Clinica Pediatrica, Universita` di Perugia, Italy
In the Umbria Region the CF newborn screening (NBS) was carried out since
the year 2000. The tests were run in the “CRI Laboratory” in Rome using the
IRT1/OLA31/IRT2 protocol [1]. For all positive subjects more detailed tests were
suggested in order (a) to ﬁnd mutations not contained in the OLA31 panel, (b) to
study the available family members to ﬁnd CF traits and at risk couples. The whole
CF gene was studied by DGGE analysis and by sequencing in patients with positive
or borderline sweat test. In the 7 years 15 CF patients out of 50,941 newborns were
found (1:3465), 8 with the classic and 7 with the mild form. The IRT1 and OLA
positive cases for at least one mutation or IRT2 positive cases identiﬁed were 114:
79 (69%) of them did not come to our observation. Of the 35 examined subjects 13
were found to be CF affected (6 classic and 7 mild) and 22 were heterozygotes. In
6 (4 classic and 2 mild) out of 13 CF patients the genotype was already known by
the OLA panel while in 5 CF patients (1 classic and 4 mild) only one mutation was
detected and in 2 CF patients (1 classic and 1 mild) the OLA panel was negative. The
other 2 patients had a clinical diagnosis as the IRT test was negative: they showed
a classic CF and the diagnosis was conﬁrmed by sweat test and identiﬁcation of
the CFTR gene mutations. The IRT assay, even with the 63% of false positive
results, was very useful in the identiﬁcation of the CFTR gene mutations in both
the homozygous and heterozygous subjects. In our experience the IRT positive cases
gave us the possibility to perform the appropriate genetic counselling followed by
the cascade screening and 6 new at risk couples and 2 atypical CF were detected. On
the contrary the IRT test failed to detect 2 out of 8 classical CF and the OLA in our
population was able to ﬁnd 65.38% of the mutations (17 out of 26) in 13 patients
with the IRT positive test. Our data suggest that the NBS for CF has a great poten-
tiality in the prospective prevention by means of the genetic counselling followed by
cascade screening. The need exists for a better knowledge of the prevention power of
the NBS program by the medical staff and by the families of the screened subjects.
Even if in the last few years the number of the people coming to have more detailed
genetic analysis after a positive NBS test is increasing, we think that more attention
has to be spent to suggest further investigation for the maximum preventive effect.
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The most widespread strategy of neonatal screening for CF consists in the mea-
surement of immunoreactive trypsinogen (IRT) from dried blood spots coupled
with CFTR mutation analysis. However, this strategy is complicated by the high
cost of DNA analysis, the need for an informed consent and of genetic counselling.
Moreover, the false positive rate of the IRT assay is quite high (1−2%) resulting in
too many unnecessary DNA tests. Thus, alternative markers are being investigated
to avoid these drawbacks. Pancreatitis-associated protein (PAP) is a stress protein
synthesized by the diseased pancreas, shown to be elevated in newborns with CF
and potentially useful in combination with IRT to ameliorate speciﬁcity of the
screening strategy. On these bases, a multi-center feasibility study including two
sites in USA, one in Germany and one in Italy has been performed with the aim
to assess the usefulness of the combined IRT-PAP CF protocol against the more
traditional IRT/CFTR strategy. Measurement of IRT and PAP was performed in
n=18080 neonates. IRT was detected by a time resolved ﬂuoroimmunoassay (Perkin-
Elmer Life Sciences, Turku, Finland) in dried blood spots collected at age 3−5 days.
PAP was tested by a novel two site-ﬂuoroimmunometric assay provided by Perkin-
Elmer. Based on the calculation of the percentiles of data obtained in the different
centres, hypothetical cut-offs were set at IRT>50 ng/mL and PAP >1.8 ng/mL
or IRT>100 ng/mL and PAP>1.0 ng/mL. IRT/PAP strategy may be a promising
alternative since it could decrease the number of mutation analysis required (down
to 0.3%) thereby decreasing the cost of the screening as well as the number of
carriers identiﬁed. Limitations of this study include the rather small sample size
that does not allow the evaluation of the sensitivity in detecting mild CF forms.
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Aim: Nebulization of inhaled drugs has improved in the past years thanks to the
development of a new generation of nebulizers, characterized by greater efﬁciency,
portability and shorter nebulization times. These achievements in aerosol delivery
may improve quality of life and adherence to therapy in cystic ﬁbrosis (CF) patients.
The aim of this study was to compare in vitro performance of four devices [PARI
TurboBOY N LC PLUS (LC), PARI eFlow Rapid (eF), Optineb-ir (Op) and Akita
LC Star (Ak)] when nebulizing 4 ml of Bramitob®, a new formulation of inhaled
tobramycin developed by Chiesi Farmaceutici.
Methods: By means of a Next Generation Impactor, the aerodynamic particle
size distribution was studied evaluating the mass median aerodynamic diameter
(MMAD) and ﬁne particle fraction (FPF). Moreover, the Delivered Dose (DD) and
the duration of nebulization were measured.
Results: The MMAD was lowest with Ak, whereas higher with eF, LC and Op
(2.7mm, 4.1, 4.8 and 5.5mm respectively). The FPF was higher with Ak and eF
(77.3 and 66mg) and lower with LC and Op (50.4 and 44.2mg). The DD was
similar with eF, LC and Op (86, 81.6 and 87.9mg) but was much higher with Ak
(147.2mg). Nebulization time was lowest with eF (5.5min) followed by LC and
Op (7.4 and 9.9min respectively), whereas much longer with Ak (24.3min).
Conclusions: Optineb-ir and eFlow Rapid are characterized by an aerodynamic
particle size distribution and a delivered dose similar to that of PARI TurboBOY N
LC PLUS, which is the device used in the clinical trials conducted with Bramitob®.
However, small differences, such as those observed in the nebulization time, may
represent an important feature when considered in the daily therapies that CF
patients undergo.
